EGFR and neoplasm: Tumours acquiring tamoxifen resistance over time have an adaptive change in growth factor signalling (such as a reduction in PgR expression, increased EGFR expression), therefore Src kinase being downstream of such signalling networks may not become fully active until later during the development of tamoxifen resistance.